Teva Pharmaceutical Industries Limited
TEVA
$31.66
$0.250.80%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.02% | 2.07% | 3.82% | 4.40% | 9.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.02% | 2.07% | 3.82% | 4.40% | 9.81% |
| Cost of Revenue | -0.46% | 1.85% | 3.38% | 3.40% | 1.68% |
| Gross Profit | 0.51% | 2.31% | 4.29% | 5.48% | 19.43% |
| SG&A Expenses | 4.16% | 5.12% | 5.42% | 5.80% | 6.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 120.00% | 236.36% | 358.33% | 0.00% | -67.21% |
| Total Operating Expenses | 1.17% | 2.72% | 4.36% | 4.15% | 2.81% |
| Operating Income | -4.02% | -0.29% | 1.80% | 5.41% | 44.45% |
| Income Before Tax | 269.94% | 51.05% | 36.78% | -106.43% | 77.27% |
| Income Tax Expenses | -65.41% | -84.68% | 2,153.85% | 11,350.00% | 574.51% |
| Earnings from Continuing Operations | 154.31% | 78.27% | -68.80% | -218.02% | 49.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -80.23% | -98.32% | -88.78% | 471.43% | 180.43% |
| Net Income | 174.24% | 65.12% | -168.48% | -192.68% | 58.96% |
| EBIT | -4.02% | -0.29% | 1.80% | 5.41% | 44.45% |
| EBITDA | -4.03% | -1.47% | -0.67% | 1.80% | 26.71% |
| EPS Basic | 173.52% | 63.80% | -165.52% | -188.79% | 59.79% |
| Normalized Basic EPS | -13.92% | -15.42% | -10.92% | 28.99% | 85.37% |
| EPS Diluted | 169.57% | 60.64% | -161.53% | -181.76% | 59.09% |
| Normalized Diluted EPS | -14.43% | -15.40% | -10.59% | 30.15% | 85.17% |
| Average Basic Shares Outstanding | 1.22% | 1.18% | 1.16% | 1.01% | 0.96% |
| Average Diluted Shares Outstanding | 2.01% | 1.28% | 0.95% | 0.33% | 1.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |